دورية أكاديمية
أعرض في EDS

Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment

التفاصيل البيبلوغرافية
العنوان: Epidermal growth factor receptor exon 20 mutation in lung cancer: types, incidence, clinical features and impact on treatment
المؤلفون: Noronha V, Choughule A, Patil VM, Joshi A, Kumar R, Susan Joy Philip D, Banavali S, Dutt A, Prabhash K
المصدر: OncoTargets and Therapy, Vol Volume 10, Pp 2903-2908 (2017)
بيانات النشر: Dove Medical Press, 2017.
سنة النشر: 2017
المجموعة: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
مصطلحات موضوعية: Exon 20, Lung cancer, EGFR mutation, TKI resistance, Insertions., Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
الوصف: Vanita Noronha,1,* Anuradha Choughule,2,* Vijay M Patil,1,* Amit Joshi,1 Rajiv Kumar,3 Deepa Susan Joy Philip,1 Shripad Banavali,2 Amit Dutt,4 Kumar Prabhash2 1Department of Medical Oncology, 2Department of Medical Oncology-Molecular Laboratory, 3Department of Pathology, Tata Memorial Hospital, 4Dutt Lab, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Mumbai, India *These authors contributed equally to this work Background: There are limited data available on the treatment and outcome of epidermal growth factor receptor (EGFR) exon 20-mutated lung cancer patients. Hence, we planned an analysis of the demographic details, clinical profile and survival of lung cancer patients with exon 20 mutations. We compared our results to patients with EGFR tyrosine kinase inhibitor (TKI)-sensitizing activating and EGFR/anaplastic lymphoma kinase (ALK)-negative mutations. Methods: This was a retrospective analysis of lung cancer patients who were treated at our center between January 2010 and August 2014. We reviewed the results of EGFR mutation testing by real-time polymerase chain reaction and Sanger sequencing. We also reviewed the data relating to baseline demographics, clinical profile, patient treatment and outcome measures in terms of response and overall survival (OS). Results: A total of 580 patients fulfilled the selection criteria. In all, 227 (39.1%) patients had EGFR TKI-sensitizing activating mutations, 20 (3.4%) patients had exon 20 insertion mutations and 333 patients were EGFR/ALK mutation negative (57.5%). The median OS was 5 months (95% confidence interval [CI] 0.17–9.8 months) in exon 20 insertion mutations, 16.1 months (95% CI 12.8–19.5 months) in EGFR TKI-sensitizing activating mutations and 10 months (95% CI 7.9–12.1 months) in EGFR/ALK mutation-negative patients. The median OS was significantly better for the EGFR TKI-sensitizing activating mutation group (P=0.000, log-rank test) and for the EGFR/ALK-negative group (P=0.037, log-rank test) compared to the exon 20-mutated group. Conclusion: Exon 20 mutation results in a poorer OS prognosis compared to EGFR- and ALK-negative patients and patients harboring EGFR TKI-sensitizing activating mutations. The incidence of de novo exon 20 insertions was 3.4%. Different types of exon mutations seem to have different outcomes. Keywords: exon 20, lung cancer, EGFR mutation, TKI resistance, insertions
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1178-6930
24262455
Relation: https://www.dovepress.com/epidermal-growth-factor-receptor-exon-20-mutation-in-lung-cancer-types-peer-reviewed-article-OTT; https://doaj.org/toc/1178-6930
URL الوصول: https://doaj.org/article/a7b24262455e463c8bacac4de5ba223b
رقم الأكسشن: edsdoj.7b24262455e463c8bacac4de5ba223b
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:11786930
24262455